Intellia awarded innovation passport in UK for NTLA-2002

Intellia Therapeutics announced the U.K. Medicines and Healthcare products Regulatory Agency MHRA has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema HAE . The Innovation Passport is the point of entry into the U.K.’s Innovative Licensing and Access Pathway ILAP , which is designed to accelerate time to market and facilitate patient access to innovative medicines."With the high treatment burden of currently available chronic therapies for hereditary angioedema, we are pleased to receive the ILAP designation, which will enable Intellia to further accelerate the clinical development of NTLA-2002," said Intellia President and Chief Executive Officer John Leonard, M.D. "We expect to begin the Phase 2 portion of the NTLA-2002 clinical study in the first half of this year, and we look forward to working with the U.K. and other regulatory agencies to bring this investigational single-dose genome editing treatment to patients as quickly as possible."